Milan Kalawadia

CEO, North America, Dr. Reddy's Laboratories Ltd.

Search every verified Milan Kalawadia interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In August 2025, Milan Kalawadia, CEO of North America at Dr. Reddy's Laboratories, appeared on the podcast "The Business of Biotech" to discuss the company's partnership with Coya Therapeutics on COYA 302, an investigational immunotherapy for ALS. Kalawadia described the collaboration as pairing Dr. Reddy's manufacturing and commercialization capabilities with Coya's scientific expertise, and noted that the timing aligns with the company's expansion into biosimilars and its broader interest in innovative medicine, which he attributed to the founding vision of Dr. Anji Reddy. Kalawadia also discussed Dr. Reddy's strategic priorities, including growth initiatives in self-care wellness and biosimilars, as well as the launch of its first GLP-1 product, semaglutide, in Canada, which he identified as a top near-term focus. He commented on the U.S. biosimilar market, explaining that pricing depends on the segment—medical benefit versus pharmacy benefit—and the number of competitors for a given product.